Leerink analyst Marc Goodman lowered his price target for Neurocrine to $84 from $110, while reiterating a Market Perform rating on the shares. In Tourette syndrome, the analyst removed his sales forecasts due to the negative readout of T-Force GOLD and in Tardive dyskinesia, he adjusted his peak sales estimates from about $2.5B to $2.0B.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSRoot (ROOT) up... To see the rest of the story go to thefly.com. See Story Here

Neurocrine Biosciences announced the FDA has approved INGREZZA SPRINKLE, or valbenazine, capsules, a new oral granules formulation of INGREZZA, or valbenazine, capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. INGREZZA SPRINKLE provides an alternative administration option for those who experience dysphagia or have difficulty swallowing. Like the original formulation of INGREZZA capsules, INGREZZA SPRINKLE offers simple dosing that's always one capsule, once daily with no complex titration. INGREZZA is the only selective vesicular monoamine transporter 2 inhibitor that offers three effective dosages that can be adjusted by the healthcare provider based on patient response and tolerability. INGREZZA SPRINKLE offers the same dosage strengths, and the contents of the capsules can be easily sprinkled on soft food for oral administration.